Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients

  • Authors:
    • Matthew P. Cunningham
    • Sharadah Essapen
    • Hilary Thomas
    • Margaret Green
    • David P. Lovell
    • Clare Topham
    • Christopher Marks
    • Helmout Modjtahedi
  • View Affiliations

  • Published online on: February 1, 2006     https://doi.org/10.3892/ijo.28.2.329
  • Pages: 329-335
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Signalling via the insulin-like growth factor-I receptor (IGF-IR) has been associated with resistance to anti- epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER-2)-based therapies in the experimental system, but the coexpression and clinical significance of the IGF-IR, EGFR and HER-2 in cancer patients remains unclear. IGF-IR, EGFR, and HER-2 status was assessed retrospectively in tumour specimens from 87 Dukes' C colorectal cancer patients using immunohistochemistry. Sections were scored by the percentage of positive cells (membrane and cytoplasmic) and intensity of staining. The association between receptor coexpression and clinicopathological parameters and overall survival were evaluated using univariate and multivariate (Cox) analysis. Overall, 93, 83 and 89% of the cases expressed IGF-IR, EGFR and HER-2, respectively. While 60% of the cases expressed membranous IGF-IR, the expression of EGFR and HER-2 was predominantly cytoplasmic. Coexpression of the IGF-IR, EGFR and HER-2 was present in tumours from 75% of the patients. No significant association was found between the expression or coexpression of total IGF-IR, EGFR and HER-2 and clinicopathological parameters or overall survival. Our results indicate that coexpression of IGF-IR, EGFR and HER-2 is common in Dukes' C colorectal cancer, warranting further investigation on the co-targeting of such receptors in colorectal cancer patients.

Related Articles

Journal Cover

February 2006
Volume 28 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C and Modjtahedi H: Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 28: 329-335, 2006
APA
Cunningham, M.P., Essapen, S., Thomas, H., Green, M., Lovell, D.P., Topham, C. ... Modjtahedi, H. (2006). Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. International Journal of Oncology, 28, 329-335. https://doi.org/10.3892/ijo.28.2.329
MLA
Cunningham, M. P., Essapen, S., Thomas, H., Green, M., Lovell, D. P., Topham, C., Marks, C., Modjtahedi, H."Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients". International Journal of Oncology 28.2 (2006): 329-335.
Chicago
Cunningham, M. P., Essapen, S., Thomas, H., Green, M., Lovell, D. P., Topham, C., Marks, C., Modjtahedi, H."Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients". International Journal of Oncology 28, no. 2 (2006): 329-335. https://doi.org/10.3892/ijo.28.2.329